Weiss, Glen J

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. [electronic resource] - Investigational new drugs 02 2018 - 85-95 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1573-0646

10.1007/s10637-017-0491-7 doi


Administration, Oral
Aged
Antineoplastic Agents--administration & dosage
Cell Cycle Proteins--antagonists & inhibitors
Dose-Response Relationship, Drug
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
Neutropenia--chemically induced
Protein Kinase Inhibitors--administration & dosage
Protein Serine-Threonine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins--antagonists & inhibitors
Thrombocytopenia--chemically induced
Treatment Outcome
Polo-Like Kinase 1